JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Danaher Corp

Gesloten

SectorGezondheidszorg

223.58 0.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

223.09

Max

223.98

Belangrijke statistieken

By Trading Economics

Inkomsten

-399M

555M

Verkoop

195M

5.9B

K/W

Sectorgemiddelde

44.433

37.461

EPS

0.77

Dividendrendement

0.56

Winstmarge

9.35

Werknemers

61,000

EBITDA

-455M

1.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+9.17% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.56%

2.33%

Volgende dividenddatum

31 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

15B

150B

Vorige openingsprijs

223.09

Vorige sluitingsprijs

223.58

Nieuwssentiment

By Acuity

39%

61%

111 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Danaher Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 okt 2025, 17:41 UTC

Winsten

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21 okt 2025, 10:28 UTC

Winsten

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22 jul 2025, 11:32 UTC

Winsten

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 jul 2025, 10:42 UTC

Winsten

Danaher Posts Higher 2Q Sales, Lower Profit

22 apr 2025, 10:34 UTC

Winsten

Danaher 1Q Results Decline But Top Estimates

21 okt 2025, 10:02 UTC

Winsten

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21 okt 2025, 10:01 UTC

Winsten

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21 okt 2025, 10:01 UTC

Winsten

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21 okt 2025, 10:00 UTC

Winsten

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21 okt 2025, 10:00 UTC

Winsten

Danaher 3Q Net $908M >DHR

21 okt 2025, 10:00 UTC

Winsten

Danaher 3Q Sales $6.05B >DHR

21 okt 2025, 10:00 UTC

Winsten

Danaher 3Q Adj EPS $1.89 >DHR

21 okt 2025, 10:00 UTC

Winsten

Danaher 3Q EPS $1.27 >DHR

22 jul 2025, 10:03 UTC

Winsten

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 jul 2025, 10:03 UTC

Winsten

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 jul 2025, 10:02 UTC

Winsten

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 jul 2025, 10:01 UTC

Winsten

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 jul 2025, 10:00 UTC

Winsten

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 jul 2025, 10:00 UTC

Winsten

Danaher 2Q Net $555M >DHR

22 jul 2025, 10:00 UTC

Winsten

Danaher 2Q Sales $5.9B >DHR

22 jul 2025, 10:00 UTC

Winsten

Danaher 2Q Adj EPS $1.80 >DHR

22 jul 2025, 10:00 UTC

Winsten

Danaher 2Q EPS 77c >DHR

22 jul 2025, 09:34 UTC

Populaire aandelen

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 jul 2025, 16:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 apr 2025, 10:02 UTC

Winsten

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 apr 2025, 10:02 UTC

Winsten

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 apr 2025, 10:02 UTC

Winsten

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 apr 2025, 10:01 UTC

Winsten

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 apr 2025, 10:01 UTC

Winsten

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 apr 2025, 10:00 UTC

Winsten

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

Peer Vergelijking

Prijswijziging

Danaher Corp Prognose

Koersdoel

By TipRanks

9.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 243.45 USD  9.17%

Hoogste 260 USD

Laagste 220 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Danaher Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Technische score

By Trading Central

189.8851 / 196.5Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

111 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat